Valion Bio closes $700,000 Series B preferred-stock and warrant sale to 3i
On November 6, 2026, Valion Bio issued 700 Series B non-voting convertible preferred shares and warrants for 21,539 common shares to 3i, LP for $700,000. The warrants have an initial exercise price of $0.5182 per common share, and the securities were sold in reliance on Section 4(a)(2) and/or Rule 506(b) exemptions. The side letter provides registration rights and extends the Series B purchase agreement termination date to December 9, 2027.
Key takeaways
Closing consideration: 3i, LP paid Valion Bio $700,000 for the Series B securities on November 6, 2026.
Securities issued: Valion Bio issued 700 Series B non-voting convertible preferred shares and warrants to purchase 21,539 common shares.
Warrant pricing: The Series B warrants have an initial exercise price of $0.5182 per common share.
Unregistered sale: The securities were issued in reliance upon an exemption under Section 4(a)(2) and/or Rule 506(b) of the Securities Act.
Registration rights: Valion Bio agreed to use commercially reasonable efforts to file a resale registration statement within 30 days after closing, seek effectiveness within 60 days after closing, and maintain availability for resale until the securities are sold or no longer require registration.
Agreement deadline: The termination date for closings under the Series B Preferred Purchase Agreement was extended to December 9, 2027.
Remaining Series B option: As of November 6, 2026, 3i retained an option, but not an obligation, to purchase up to 1,550 additional Series B preferred shares and corresponding warrants for up to $1,550,000.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow VBIO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.